ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA

Transcription

1 ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA

2 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions and expectations that involve uncertainties or risks. These uncertainties and risks include, but are not limited to, those described in the filings we make with the U.S. Securities and Exchange Commission (SEC). Actual results may differ materially from anticipated results. Forward-looking statements are made as of today's date, and we undertake no duty to update them or any of the information contained in this presentation ADA Orlando, FL 2

3 HOOMAN HAKAMI EXECUTIVE VICE PRESIDENT & PRESIDENT DIABETES GROUP 2018 ADA Orlando, FL 3

4 DIABETES GROUP EXECUTIVE SUMMARY Strong legacy & brand highest share position in almost a decade In many ways, just getting started Above corporate average growth Sensor pull-through & conversion of MDI in core pump BU Launch of stand-alone CGM targeting $1B+ category growing 30% Sustainability of growth High differentiation & profitability we ve dramatically improved Innovation in decision support & patient engagement Outcomes focus in products & goto-market 2018 ADA Orlando, FL 4

5 DIABETES STRUCTURE & OPERATING FRAMEWORK REPOSITIONING THE BUSINESS FOR ABOVE CORPORATE AVERAGE GROWTH PRODUCT LINE DIVISION GROUP Administrator Focus Disease / IPU Focused Advanced Insulin Management (AIM) Insulin pump therapy systems Integrated CGM Consumables & accessories Diabetes Group Multiple Daily Injection Solutions (MDIS) Standalone CGM Injection port Diabetes mgmt. programs & services Emerging Technologies Non-Intensive Diabetes Therapies (NDT) Professional CGM Diabetes mgmt. programs & services Diabetes mgmt. programs & services 2018 ADA Orlando, FL 5

6 EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT DISEASE STATE TYPE 2 TYPE 1 REGIMEN PREVALENCE DIET & EXERCISE 60MM ORALS 110MM BASAL 20MM PREMIX 15MM MDI 20MM PUMPS 1.1MM AIM AIM Advanced Insulin Management Patients Served: T1D & T2D on pumps Call point: Endocrinologists Solutions: Insulin pump therapy, consumables & accessories GOAL Artificial Pancreas as standard of care Core business Pumps & CGM ~70% global share 8% penetrated 2018 ADA Orlando, FL 6

7 THE MINIMED 670G SYSTEM NOW APPROVED FOR CHILDREN 7+ Features our most advanced SmartGuard technology, which constantly self-adjusts to allow patients to spend more Time in Range (TIR) Includes our newest and most accurate Guardian TM Sensor ADA Orlando, FL 7

8 NEW CE MARK! THE MINIMED 670G SYSTEM FOR CHILDREN 7+ Advances the ability to automatically suspend & resume insulin delivery to the next level by automating self-adjusting basal insulin every 5 minutes providing the most advanced algorithm that proactively drives Time in Range improvement ADA Orlando, FL 8

9 VALUE-BASED HEALTHCARE PARTNERSHIP PREFERRED PARTNERSHIP STATISTICS Share Revenue EBITA From To 70% 92% VALUE BASED HEALTHCARE AGREEMENT COHORTS: PATIENTS ON PUMP THERAPY Year 1 COMPARISON GROUP: MDI PATIENTS OUTCOME MEASURES: HOSPITALIZATIONS & TOTAL COST 27% REDUCTION IN PREVENTABLE HOSPITALIZATIONS UP TO 14% REDUCTION IN TOTAL MEDICAL COSTS SHARED SAVINGS BETWEEN UHG & MEDTRONIC Investor ADA Orlando, Day FL 9 9

10 THE NEW MINIMED TM 670G SYSTEM PERFORMANCE GUARANTEE FLAT REIMBURSEMENT MODEL TO MITIGATE HOSPITAL COSTS The MiniMed TM 670G System Performance Guarantee $25,000 total reimbursement value per patient over 4 years Year 1 Year 2 Year 3 New program for payers Diabetes-related Inpatient Hospitalization $6000 Inpatient hospitalization claim coded DRG of 637, 638, or 639 (E1010-E109) Diabetes-related Emergency Room Admission $2500 ER visit coded with primary ICD-10 diagnosis of E10* type 1 diabetes, as specified by 2018 CMS ICD-10-CM 2018 ADA Orlando, FL 10

11 DISRUPTIVE CLOSED LOOP ECOSYSTEM Launched Near Long GOALS ALGORITHM MM670G System Outcomes Peds indication Advanced HCL Auto-correction bolus >80% TIR goal Personalized CL Advanced adaptation >85% TIR goal Limited patient interaction SENSOR Guardian Sensor 3 Arm labeling 9% MARD Project Harmony Adaptive cals & non-adjunctive Project Unity Miniaturization, no cals, d wear, disposable Wear & forget USABILITY CareLink Web-based data mgmt. SmartPhone App Data viewing & pump control Project Duo Integrated canula & sensor Simple & discreet INSIGHTS System Performance Report Data-guided system & behavior optimization Virtual Support Augmented assistance & AI guided optimization Proactive Triage Customer Service & HCP preventative mgmt Differentiated Outcomes Note: future concepts; not investigational nor commercially available 2018 ADA Orlando, FL 11

12 LAURA STOLTENBERG VICE PRESIDENT & GM MULTIPLE DAILY INJECTION SOLUTIONS 2018 ADA Orlando, FL 12

13 EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT DISEASE STATE REGIMEN PREVALENCE DIET & EXERCISE 60MM ORALS 110MM TYPE 2 BASAL 20MM PREMIX 15MM MDIS MDI 20MM TYPE 1 PUMPS 1.1MM Adjacent category MDIS Multiple Daily Injection Solutions Patients Served: T1D & T2D on multiple daily injections Call point: Insulin prescribing PCPs/GPs & Endos Solutions: Standalone CGM, injection port GOAL Smart, connected solutions that empower patients & help drive outcomes Personal CGM <5% share ~20% penetrated MDIS Solutions Therapy Innovation Decision Support Patient Engagement 2018 ADA Orlando, FL 13

14 GUARDIAN TM CONNECT WITH SUGAR.IQ LAUNCHING THE MDIS BUSINESS Expanding Access First stand-alone CGM launched 20MM MDI patients globally Empowering Patients with Smarter Tools Predictive alerts + Sugar.IQ Insights No dedicated receiver 12 month transmitter Arm indication enhanced accuracy (9.1% MARD) Designed to Help Improve Outcomes time in range hypo / hyperglycemia frequency Prediction feature available in a future release Data for presentation purposes only 2018 ADA Orlando, FL 14

15 SMART CGM HELPS MDI PATIENTS MAKE SMARTER DECISIONS SO THEY CAN FOCUS ON LIFE, NOT ON LEVELS In-Room Video URL: Investor Day 15

16 CLINICAL OBSERVATIONS BETTER BEHAVIOR LEADING TO POSITIVE OUTCOMES AGGREGATE DATA p =0.01 p <0.001 p < ,356 Total Users Calendar days Time In Range 30 mins per day 6 mins per day 231 Users with 2+ weeks of data after using Sugar.IQ Time >180 mg/dl (Avg. per day) Time <70 mg/dl (Avg. per day) INSIGHTS p <0.001 p < ,761 Insights Generated 655 Hypo-related Insights Hypo + Hyper 1.22 episodes 0.95 episodes 699 Hyper-related Insights # of episodes High Episodes / Month (180 mg/dl > 120 mins) Low Episodes / Month (70 mg/dl > 20 mins) Usage of Sugar.IQ app was analyzed based on data from 256 randomly offered real-world MiniMed 530G users from April to August ADA Orlando, FL 16

17 SUGAR.IQ DIABETES ASSISTANT AI PERSONALIZATION = ACTIONABLE INSIGHTS AI-Based Assistant continually analyzes multiple data sources Retrospective Insights reveal hidden patterns INSULIN INSIGHTS FOOD INSIGHTS MOTIVATIONAL INSIGHTS ROUTINE & TIME OF DAY INSIGHTS Glycemic Assist lets patients track glucose response to new foods and routines My Data tracks time in range and other key metrics in real time LOW SG FORECAST Hypo prediction up to 4 hours in advance 2018 ADA Orlando, FL 17

18 BUILDING A COMPLETE ECOSYSTEM FOR MDI PATIENTS Launched Near Long GOALS SENSOR Guardian Connect + Guardian Sensor 3 Arm label, 9% MARD Project Harmony Adaptive calibrations & non-adjunctive Project Unity Smaller, no cals, 10-14d, disposable Comfortable & Reliable 360 o DATA Patient Logging Multiple in-app tools meals, activity, insulin Automated Capture Insulin dose capture + advanced food logging Contextual Fully automated based on contextual signals 360 o Patient View INSIGHTS Sugar.IQ (US) Actionable glucose insights Glucose Prediction AI-based 4 hour forecast ~90% accuracy Therapy Guidance AI-based meal and correction bolus Know. Predict. Coach. ECOSYSTEM Physician Web-based data mgmt. Patient Care Plans Interactive HCP+patient for remote therapy optimization Population Management Population-level management tools Linked Ecosystem & Optimized outcomes Note: future concepts; not investigational nor commercially available 2018 ADA Orlando, FL 18

19 SHERI DODD VICE PRESIDENT & GM NON-INTENSIVE DIABETES THERAPIES 2018 ADA Orlando, FL 19

20 EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT DISEASE STATE REGIMEN PREVALENCE DIET & EXERCISE 90M NDT ORALS 90M TYPE 2 Diagnostic & intermittent CGM <1% share <1% penetration New market opportunity BASAL 15M PREMIX 15M GOAL Glucose as a Vital Sign MDI 16M TYPE 1 PUMPS 1.1M NDT Non-intensive Diabetes Therapies Patients Served: T2D Call point: PCPs/GPs Solutions: Professional diagnostic CGM 2018 ADA Orlando, FL 20

21 MEDTRONIC CARE MANAGEMENT SERVICES + NON-INTENSIVE DIABETES THERAPIES ADDRESSING THE NEEDS OF THE CHRONIC COMORBID POPULATION 5,600,000+ Telehealth Patient Months 19 Years Developing the Telehealth Market 95,000+ Members/ patients on Service MCMS NDT Integrated Care Management Nurses, Certified Heart Failure Nurses >20 Disease Management Protocols (physical and mental health) Clinical decision support software 2018 ADA Orlando, FL 21

22 MEDTRONIC CARE MANAGEMENT SERVICES + NON-INTENSIVE DIABETES THERAPIES SYNERGY EXAMPLE RIGHT TOOLS RIGHT PATIENTS MCMS identifies Complex Chronic Comorbid Population using risk stratification methodology HIGHEST ACUITY Remote Patient Monitoring Guardian Connect MiniMed 670G MCMS further Risk Stratifies populations into Cohorts (inc. HF, COPD, HTN, Diabetes) Further Risk Stratification to identify clinical decision support tools to inform care pathway MID-LEVEL ACUITY Guardian Connect / Sugar.IQ Inner Circle Patient Coaching Remote Patient Monitoring LOW ACUITY ipro2 with Pattern Snapshot + FoodPrint Patient Coaching IMPROVE OUTCOMES LOWER COSTS 2018 ADA Orlando, FL 22

23 NON-INTENSIVE DIABETES THERAPIES THERAPY INNOVATION PIPELINE INVESTING FOR FUTURE GROWTH LAUNCHED AND DRIVING CURRENT GROWTH FY19 / FY20 BEYOND Medtronic ipro Intelligent Therapy Recommendations Personalized Guidance Real Time Coaching Medtronic Envision Pro Medtronic Envision Real Time Note: investigational device only Note: Future concepts; not investigational nor commercially available 2018 ADA Orlando, FL 23

24 HOOMAN HAKAMI EXECUTIVE VICE PRESIDENT & PRESIDENT DIABETES GROUP 2018 ADA Orlando, FL 24

25 OUR VALUE PROPOSITION ACROSS ALL BUSINESSES Therapy Innovation Decision Support Patient Engagement VBHC Contracting 2018 ADA Orlando, FL 25

26 DIABETES GROUP CONSISTENT, SUSTAINABLE, GROWTH ABOVE CORPORATE AVERAGE GROWTH DRIVERS CATEGORY SALES 1 MARKET CAGR 2 THERAPY INNOVATION Closed Loop as Standard-of-Care Increased CGM attachment rates; Drive MDI conversions; International expansion ~$3.5B ~10% CONSISTENT EXECUTION GLOBALIZATION ECONOMIC VALUE Sustained Growth Above Corporate Average Launched Stand-Alone CGM Smart CGM system focused on outcomes Expansion into Type 2 Increase diagnostic CGM glucose as a vital sign in the management of T2 ~$1B ~26% ~$0.1B ~70% ENTERPRISE EXCELLENCE Globalization & Enterprise Excellence Clinics & care management expansion globally Leverage MDT Footprint for CGM & Customer Care 1. FY18 market estimates 2. FY17-FY22 growth estimates 2018 ADA Orlando, FL 26

27 ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA

28 APPENDIX

29 2018 ADA Orlando, FL 29